國立虎尾科技大學 |

An Introduction to Bioanalysis of Biopharmaceuticals

Record Type:	Language materials, printed : Monograph/item
Title/Author:	An Introduction to Bioanalysis of Biopharmaceuticals/ edited by Seema Kumar.
other author:	Kumar, Seema.
Description:	IX, 160 p. 25 illus., 19 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Biology. -
Online resource:	https://doi.org/10.1007/978-3-030-97193-9
ISBN:	9783030971939

An Introduction to Bioanalysis of Biopharmaceuticals
An Introduction to Bioanalysis of Biopharmaceuticals[electronic resource] /edited by Seema Kumar. - 1st ed. 2022. - IX, 160 p. 25 illus., 19 illus. in color.online resource. - AAPS Advances in the Pharmaceutical Sciences Series,572210-738X ;. - AAPS Advances in the Pharmaceutical Sciences Series,20.

Bioanalytical Support in Drug Discovery and Development,- Monoclonal Antibodies -- Antibody Drug Conjugates (ADCS) -- Bispecifics and Fusion Proteins -- Emerging Modalities-Part A- (Gene Therapy and Cell Therapy) -- Emerging Modalities Part B (Peptides, Oligonucleotide Based Therapy, Vaccines. .

The book provides a comprehensive review of the fundamental and practical aspects of bioanalytical support and the integral role it plays in the development of safe and efficacious biopharmaceutical drugs with speed and cost-effectiveness. The book focuses on a broad range of conventional and emerging biopharmaceutical modalities including monoclonal antibody-based therapeutics, gene therapy, cell therapy, peptides and oligonucleotides. The book starts with an introductory overview of bioanalysis showcasing the integral role it plays in understanding the drug disposition (pharmacokinetics/pharmacodynamics and immunogenicity) and the progression of bioanalytical strategy as the drug progresses through discovery and development stages of the program, taking into consideration the continually evolving regulatory landscape. The book further diversifies into individual biopharmaceutical modalities - monoclonal antibodies, antibody-drug conjugates, bispecifics, Fc-fusion proteins, gene therapies, cell therapies, peptides and oligonucleotides. The individual chapters focus on modality-specific bioanalytical assay strategies, critical reagents, assay formats, analytical platforms, associated bioanalytical challenges and mitigation strategies, industry best practices, and the latest understanding of regulatory guidance as applicable to the fast-growing biopharmaceutical landscape.

ISBN: 9783030971939

Standard No.: 10.1007/978-3-030-97193-9doiSubjects--Topical Terms:

599573
Biology.

LC Class. No.: QH301-705

Dewey Class. No.: 570

An Introduction to Bioanalysis of Biopharmaceuticals
LDR:03140nam a22004095i 4500 001 1082279
003 DE-He213
005 20220823133540.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030971939 $9 978-3-030-97193-9
024 7 $a 10.1007/978-3-030-97193-9 $2 doi
035 $a 978-3-030-97193-9
050 4 $a QH301-705
072 7 $a PSA $2 bicssc
072 7 $a SCI086000 $2 bisacsh
072 7 $a PSA $2 thema
082 0 4 $a 570 $2 23
245 1 3 $a An Introduction to Bioanalysis of Biopharmaceuticals $h [electronic resource] / $c edited by Seema Kumar.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a IX, 160 p. 25 illus., 19 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-738X ; $v 57
505 0 $a Bioanalytical Support in Drug Discovery and Development,- Monoclonal Antibodies -- Antibody Drug Conjugates (ADCS) -- Bispecifics and Fusion Proteins -- Emerging Modalities-Part A- (Gene Therapy and Cell Therapy) -- Emerging Modalities Part B (Peptides, Oligonucleotide Based Therapy, Vaccines. .
520 $a The book provides a comprehensive review of the fundamental and practical aspects of bioanalytical support and the integral role it plays in the development of safe and efficacious biopharmaceutical drugs with speed and cost-effectiveness. The book focuses on a broad range of conventional and emerging biopharmaceutical modalities including monoclonal antibody-based therapeutics, gene therapy, cell therapy, peptides and oligonucleotides. The book starts with an introductory overview of bioanalysis showcasing the integral role it plays in understanding the drug disposition (pharmacokinetics/pharmacodynamics and immunogenicity) and the progression of bioanalytical strategy as the drug progresses through discovery and development stages of the program, taking into consideration the continually evolving regulatory landscape. The book further diversifies into individual biopharmaceutical modalities - monoclonal antibodies, antibody-drug conjugates, bispecifics, Fc-fusion proteins, gene therapies, cell therapies, peptides and oligonucleotides. The individual chapters focus on modality-specific bioanalytical assay strategies, critical reagents, assay formats, analytical platforms, associated bioanalytical challenges and mitigation strategies, industry best practices, and the latest understanding of regulatory guidance as applicable to the fast-growing biopharmaceutical landscape.
650 0 $a Biology. $3 599573
650 0 $a Pharmaceutical chemistry. $3 581965
650 0 $a Biochemistry. $3 582831
650 0 $a Pharmacology. $3 583819
650 0 $a Cytology. $3 599554
650 1 4 $a Biological Sciences. $3 790542
650 2 4 $a Pharmaceutics. $3 1366841
650 2 4 $a Biological Chemistry. $3 1387889
650 2 4 $a Cell Biology. $3 593889
700 1 $a Kumar, Seema. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1387888
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030971922
776 0 8 $i Printed edition: $z 9783030971946
776 0 8 $i Printed edition: $z 9783030999988
830 0 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 20 $3 1255084
856 4 0 $u https://doi.org/10.1007/978-3-030-97193-9
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)